In particular, CDKL2 is overexpressed in mesenchymal breast cancer cells compared with epithelial cells, and its overexpression is negatively correlated with disease‐free survival.23 In summary, the described studies have revealed crucial roles of CDKLs in EMT and carcinogenesis and suggested that CDKLs could be potential biomarkers for prognosis as well as gene targets for cancer therapy. This evidence concerns the gene CDKL2 and cancer.